FDA WidgetGate: Implications and Recommendations

Intouch Solutions' Official POV

For those of you following the commentary on FDA's letter to Novartis regarding social sharing widgets (can we call it WidgetGate for fun?!), Intouch Solutions has some new information and recommendations to share with you.

Yesterday I posted a recap, analysis, and collection of musings and opinions on the subject. Today, I'd like to share a more official point-of-view document researched and issued by our Emerging Media team. This Point-of-View (POV) document was issued exclusively to Intouch Solutions clients late Friday and is an extensive sum-total of many discussions and brains noodling the different angles of the situation. It's seven pages long ... and yet we still feel like there's so much more to say!

We hope you all find the POV helpful as you sort through your own situations and the variety of opinions on the subject. After all, there really isn't one right answer - each pharma company will need to weigh their own products, programs, goals, social strategy, and current situation against their own risk threshold.

Credit for writing the POV goes to Sean Nicholson, Sarah Waldschmidt, Jim Dayton, (and me), plus many others here that contributed to the collective knowledge. And we're not done yet - expect more updates soon.

Interested in your thoughts ... how does all the commentary compare with what's really happening inside pharma's walls?